You are here: Industry Insights > Keytruda

News List

Keytruda has a blockbuster market not factored into Merck’s forecasts—China fiercepharma
March 18, 2019
Merck & Co.’s Keytruda is already the best-selling immuno-oncology drug on the market, but as one group of analysts sees it, the drug still has one key upside opportunity that’s not yet calculated into forecasts: the Chinese market.
Merck's Keytruda hits the skids in pivotal trial, putting its liver cancer nod at risk fiercepharma
February 24, 2019
Merck & Co.’s immunotherapy Keytruda has been hitting its trial targets so often, it’s tempting to think it can't miss. But it can—and Tuesday’s data in liver cancer proves it.
Merck's Keytruda hits the skids in pivotal trial, putting its liver cancer nod at risk fiercepharma
February 21, 2019
Merck & Co.’s immunotherapy Keytruda has been hitting its trial targets so often, it’s tempting to think it can't miss. But it can—and Tuesday’s data in liver cancer proves it.
Keytruda gets okay from FDA for adjuvant melanoma pharmaphorum
February 21, 2019
The US FDA has approved Merck & Co’s Keytruda as an adjuvant treatment for patients with melanoma who have had surgery but still show some evidence of cancer in their lymph nodes.
Merck initiates three Phase III trials into Keytruda for prostate cancer pharmaceutical-technology
February 18, 2019
As a result of promising data from its Phase Ib/II KEYNOTE-365 trial, Merck has announced three new Phase III trials into the safety and efficacy of Keytruda (pembrolizumab) for patients with metastatic castration-resistant prostate cancer....
Merck's Keytruda looks to zoom past Opdivo with fast head and neck cancer review fiercepharma
February 12, 2019
Merck & Co.’s Keytruda is duking it out with Bristol-Myers Squibb’s Opdivo in the head and neck cancer marketplace, but Keytruda just took one step toward a green light that would give it a big edge.
Merck bumps Keytruda credibility with real doctor appearance in latest ‘Tru’ patient ads fiercepharma
January 17, 2019
Merck & Co. is changing the game again in oncology ads, this time putting a real doctor to work in its Keytruda patient campaign. The latest additions to the multichannel "It's Tru" work include two TV ads, one with oncologist Goetz Kloecker, M.D., alone
Keytruda cuts risk of death by 31% in esophageal cancer trial pharmaphorum
January 16, 2019
MSD’s Keytruda has cut the risk of death by 31% in patients with esophageal or esophagogastric junction carcinoma or adenocarcinoma who progressed after standard therapy.
Merck's Keytruda slashes death risk by 31% in esophageal cancer victory fiercepharma
January 15, 2019
Back in November, Merck & Co. said its immuno-oncology star, Keytruda, had topped chemo at lengthening the lives of some esophageal cancer patients. Monday, it showed that the win was a sizable one.
OncoSec, Gynecologic Oncology Group to Conduct Study of TAVO with KEYTRUDA americanpharmaceuticalreview
January 09, 2019
OncoSec has established a collaboration with the GOG Foundation to conduct a registration-enabled study of TAVO (tavokinogene telseplasmid) in women with recurrent/persistent cervical cancer (OMS-150)......

Previous page 1 2 3 4 5 6 7 8 9 10 ... 16 17 Next page